Brief: Guardant Health Announces Multi-Year Strategic Collaboration Agreement With Merck
19/01/2026 14:32
Jan 19 (Reuters) - Guardant Health Inc GH.O: GUARDANT HEALTH ANNOUNCES MULTI-YEAR STRATEGIC COLLABORATION AGREEMENT WITH MERCK TO DEVELOP COMPANION DIAGNOSTICS AND COMMERCIALIZE NEW CANCER THERAPIES USING GUARDANT INFINITY SMART PLATFORM GUARDANT HEALTH INC - PARTNERSHIP FOR GLOBAL COMMERCIALIZATION OF DRUGS AND COMPANION DIAGNOSTICS IN US, ASIA-PACIFIC, UK, EU MARKETS Source text: ID:nBw9PV542a Further company coverage: GH.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Guardant Health
See all newsBrief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US Health Secretary Kennedy Jr. adds eight new members to key health committee (updated)
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Brief: Guardant Health To Appeal Federal District Court Judgment